Evoke Pharma, Inc. (EVOK)
NASDAQ: EVOK · Real-Time Price · USD
2.420
-0.080 (-3.20%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Company Description
Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases.
It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers.
Evoke Pharma, Inc. was incorporated in 2007 and is based in Solana Beach, California.
Evoke Pharma, Inc.
Country | United States |
Founded | 2007 |
IPO Date | Sep 25, 2013 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 3 |
CEO | Matthew D'Onofrio |
Contact Details
Address: 420 Stevens Avenue, Suite 230 Solana Beach, California 92075 United States | |
Phone | 858 345 1494 |
Website | evokepharma.com |
Stock Details
Ticker Symbol | EVOK |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001403708 |
CUSIP Number | 30049G104 |
ISIN Number | US30049G2030 |
Employer ID | 20-8447886 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Matthew J. D'Onofrio MBA | Co-Founder, Chief Executive Officer and Director |
Mark A. Kowieski CPA | Chief Financial Officer, Treasurer and Secretary |
Dr. Marilyn R. Carlson D.M.D., M.D., RAC. | Chief Medical Officer |
Christopher Quesenberry | Chief Commercial Officer - Gimoti (TM) |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 10, 2025 | ARS | Filing |
Apr 10, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 10, 2025 | DEF 14A | Other definitive proxy statements |
Mar 24, 2025 | SCHEDULE 13G/A | Filing |
Mar 21, 2025 | SCHEDULE 13G/A | Filing |
Mar 13, 2025 | 10-K | Annual Report |
Mar 13, 2025 | 8-K | Current Report |
Feb 24, 2025 | 8-K | Current Report |
Feb 3, 2025 | SCHEDULE 13D/A | Filing |
Nov 22, 2024 | 424B5 | Filing |